Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide

J. R. Sheu, T. F. Huang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Triflavin an Arg-Gly-Asp-containing snake venom peptide inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K(d) value of 7 x 10-8 M. In this study we found that 125I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1.0 mg kg-1 to rabbits it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μM) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g-1. Therefore triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.

Original languageEnglish
Pages (from-to)58-62
Number of pages5
JournalJournal of Pharmacy and Pharmacology
Volume46
Issue number1
Publication statusPublished - 1994
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide'. Together they form a unique fingerprint.

Cite this